Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | F2 | P00734 | 1/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.41 |
| ▸ | SLC18A2 | Q05940 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11812440 | 0.84 | F2 (0.44) | KMT2AMEN1MAPTRAB9AF2 | |
| SCHEMBL1494089 | 0.80 | HTR2A (0.44) | KMT2AMEN1RAB9ACYP2C19HTR2A | |
| SCHEMBL1494045 | 0.79 | ALDH1A1 (0.45) | KMT2AMEN1MAPTRAB9ATAAR1 | |
| SCHEMBL17833744 | 0.77 | CHRNA7 (0.47) | KMT2AMEN1MAPTRAB9A | |
| SCHEMBL5525796 | 0.77 | HTR2A (0.41) | RAB9ACYP2C19HTR2ACYP2D6 | |
| SCHEMBL1494085 | 0.77 | KDM4E (0.48) | MAPTRAB9ACYP2C19CYP1A2 | |
| SCHEMBL15252729 | 0.77 | KDM4E (0.46) | KMT2AMEN1MAPTRAB9ACYP2C19 | |
| SCHEMBL5525811 | 0.76 | TAS1R3 (0.40) | KMT2AMEN1MAPTRAB9AF2 | |
| SCHEMBL6255859 | 0.75 | CYP2C19 (0.49) | RAB9ACYP2C19HTR2ACYP2D6 | |
| SCHEMBL6546729 | 0.75 | SIGMAR1 (0.44) | KMT2AMEN1TAAR1SLC18A2SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120122859-A1 | METHODS OF USING DIAMINOPYRIMIDINE AS P2X3 AND P2X2/3 RECEPTOR MODULATORS FOR TREATMENT OF RESPIRATORY AND GASTROINTESTINAL DISEASES | ROCHE PALO ALTO LLC. | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122859-A1 | METHODS OF USING DIAMINOPYRIMIDINE AS P2X3 AND P2X2/3 RECEPTOR MODULATORS FOR TREATMENT OF RESPIRATORY AND GASTROINTESTINAL DISEASES | P2RX3, P2RX2, P2RX6 | KMT2A 3688/4885MEN1 4461/4885MAPT 4820/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.